HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 342 filers reported holding HALOZYME THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.30 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $472 | -99.8% | 8,290 | +48.4% | 0.00% | +100.0% |
| Q3 2021 | $227,000 | -61.5% | 5,585 | -57.0% | 0.00% | -66.7% |
| Q2 2021 | $590,000 | -29.8% | 12,990 | -35.6% | 0.00% | -25.0% |
| Q1 2021 | $841,000 | +37.6% | 20,163 | +41.0% | 0.00% | +33.3% |
| Q4 2020 | $611,000 | -12.8% | 14,297 | -68.4% | 0.00% | -40.0% |
| Q3 2019 | $701,000 | -35.5% | 45,203 | -28.6% | 0.01% | -37.5% |
| Q2 2019 | $1,087,000 | +0.9% | 63,292 | -5.4% | 0.01% | -11.1% |
| Q1 2019 | $1,077,000 | +7.6% | 66,923 | -2.2% | 0.01% | -10.0% |
| Q4 2018 | $1,001,000 | -24.5% | 68,397 | -6.2% | 0.01% | -9.1% |
| Q3 2018 | $1,325,000 | +6.2% | 72,949 | -1.4% | 0.01% | -8.3% |
| Q2 2018 | $1,248,000 | -14.9% | 73,987 | -1.1% | 0.01% | -20.0% |
| Q1 2018 | $1,466,000 | -6.0% | 74,817 | -2.8% | 0.02% | -6.2% |
| Q4 2017 | $1,559,000 | +6.3% | 76,936 | -8.8% | 0.02% | -5.9% |
| Q3 2017 | $1,466,000 | +30.1% | 84,373 | -4.0% | 0.02% | +21.4% |
| Q2 2017 | $1,127,000 | +2.5% | 87,889 | +3.6% | 0.01% | -6.7% |
| Q1 2017 | $1,100,000 | +32.5% | 84,874 | +1.0% | 0.02% | +15.4% |
| Q4 2016 | $830,000 | -58.8% | 83,997 | -49.6% | 0.01% | -62.9% |
| Q3 2016 | $2,015,000 | +21.6% | 166,764 | -4.7% | 0.04% | -18.6% |
| Q1 2016 | $1,657,000 | -30.8% | 174,985 | +26.7% | 0.04% | -30.6% |
| Q4 2015 | $2,394,000 | +47.4% | 138,155 | +14.3% | 0.06% | +34.8% |
| Q3 2015 | $1,624,000 | -99.9% | 120,899 | +8.1% | 0.05% | -13.2% |
| Q2 2015 | $2,526,386,000 | +138865.1% | 111,886 | -12.1% | 0.05% | +55.9% |
| Q1 2015 | $1,818,000 | -99.9% | 127,312 | -18.0% | 0.03% | +13.3% |
| Q4 2014 | $1,498,838,000 | +4.1% | 155,320 | -1.8% | 0.03% | 0.0% |
| Q3 2014 | $1,439,848,000 | -7.3% | 158,225 | +0.7% | 0.03% | -11.8% |
| Q2 2014 | $1,552,840,000 | +7.0% | 157,170 | +37.6% | 0.03% | -2.9% |
| Q1 2014 | $1,451,434,000 | -18.0% | 114,241 | -3.2% | 0.04% | -25.5% |
| Q4 2013 | $1,769,599,000 | +18.4% | 118,052 | -12.8% | 0.05% | +4.4% |
| Q3 2013 | $1,494,871,000 | – | 135,405 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 14,092,771 | $256,066,000 | 16.64% |
| BB BIOTECH AG | 8,247,860 | $149,864,000 | 3.97% |
| MSD Partners, L.P. | 2,245,000 | $40,792,000 | 3.07% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 428,633 | $5,969,000 | 2.84% |
| First Light Asset Management, LLC | 885,523 | $16,090,000 | 2.60% |
| SNYDER CAPITAL MANAGEMENT L P | 2,387,350 | $43,378,000 | 1.93% |
| Sterling Global Strategies LLC | 22,000 | $400,000 | 1.74% |
| Taylor Wealth Management Partners | 221,380 | $4,022,000 | 1.71% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 9,228,399 | $167,680,000 | 1.68% |
| DOHENY ASSET MANAGEMENT /CA | 124,393 | $2,260,000 | 1.18% |